FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma

The US Food and Drug Administration FDA has granted approval to Calquence acalabrutinib for the treatment of patients with mantle cell lymphoma MCL who have received at least one prior therapy Calquence is a highly-selective potent Bruton tyrosine kinase [...]

Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma

Results were recently presented at the 59th American Society of Hematology ASH Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients with previously treated cutaneous T-cell lymphoma [...]